Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel
In this study, we investigated whether the rs2125739 variant could affect paclitaxel (PTX) cytotoxicity in lung cancer cell lines. We also investigated the effect of rs2125739 on the efficacy and safety of nanoparticle albumin-bound PTX (nab-PTX) in clinical practice. The association between rs2125739 genotypes and the 50% inhibitory concentration (IC50) of PTX was investigated in 18 non-small cell lung cancer (NSCLC) cell lines, HeLa cells, and genome-edited HeLa cells. Next, blood samples from 77 patients with NSCLC treated with carboplatin plus nab-PTX were collected and analyzed for six SNPs, including rs2125739. The c...
Source: Investigational New Drugs - June 27, 2022 Category: Drugs & Pharmacology Source Type: research
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
CONCLUSION: PARP inhibitor combined with bevacizumab had good effect in the treatment of platinum-resistant recurrent ovarian epithelial carcinoma and can effectively improve the survival time and quality of life of patients.PMID:35720032 | PMC:PMC9205723 | DOI:10.1155/2022/4600145 (Source: Computational and Mathematical Methods in Medicine)
Source: Computational and Mathematical Methods in Medicine - June 20, 2022 Category: Statistics Authors: Li Sun Caixia Liu Yun Li Source Type: research
Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
To compare the prognosis of first-line systemic chemotherapy of AS (Albumin-bound paclitaxel and S-1) versus SOX (S-1 and oxaliplatin) regimen in Chinese gastric cancer patients with peritoneal metastasis. (Source: BMC Gastroenterology)
Source: BMC Gastroenterology - June 14, 2022 Category: Gastroenterology Authors: Lingyun Zhang, Jiayu Zhang, Yan Wang, Wei Li, Shan Yu, Qian Li, Yiyi Yu, Tianshu Liu and Yuehong Cui Tags: Research Source Type: research
Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
This study aimed to compare the efficacy of albumin-bound paclitaxel combined with carboplatin (Nab-TC) with that of traditional solvent-based paclitaxel combined with carboplatin (TC) as neoadjuvant chemother... (Source: BMC Women's Health)
Source: BMC Women's Health - June 11, 2022 Category: OBGYN Authors: Huan Wang, Lingyun Fan, Xia Wu and Yimin Han Tags: Research Source Type: research
Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial
CONCLUSIONS: Combination therapy of camrelizumab and albumin-bound paclitaxel and carboplatin shows promising efficacy and manageable toxicities in patients with recurrent or metastatic cervical cancer.PMID:35645118 | DOI:10.4103/jcrt.jcrt_1851_21 (Source: Cancer Control)
Source: Cancer Control - June 1, 2022 Category: Cancer & Oncology Authors: Xiaoling Zhang Jinlong Chen Naifu Liu Qian Wang Qian Wu Fufeng Gao Yingchun Sang Ping Wang Source Type: research
Cancers, Vol. 14, Pages 2618: Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunocompetent Orthotopic Murine Model
mad
Sameer H. Patel
Pancreas ductal adenocarcinoma (PDAC) is one the most aggressive cancers and associated with very high mortality, requiring the development of novel treatments. The mitochondrial voltage-gated potassium channel, Kv1.3 is emerging as an attractive oncologic target but its function in PDAC is unknown. Here, we evaluated the tissue expression of Kv1.3 in resected PDAC from 55 patients using immunohistochemistry (IHC) and show that all tumors expressed Kv1.3 with 60% of tumor specimens having high Kv1.3 expression. In Pan02 cells, the recently developed mitochondria-targeted Kv1.3 inhibitors PCARBTP a...
Source: Cancers - May 25, 2022 Category: Cancer & Oncology Authors: Weiwei Li Gregory C. Wilson Magdalena Bachmann Jiang Wang Andrea Mattarei Cristina Paradisi Michael J. Edwards Ildiko Szabo Erich Gulbins Syed A. Ahmad Sameer H. Patel Tags: Article Source Type: research
Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial
Conclusions: Combination therapy of camrelizumab and albumin-bound paclitaxel and carboplatin shows promising efficacy and manageable toxicities in patients with recurrent or metastatic cervical cancer. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - May 20, 2022 Category: Cancer & Oncology Authors: Xiaoling Zhang Jinlong Chen Naifu Liu Qian Wang Qian Wu Fufeng Gao Yingchun Sang Ping Wang Source Type: research
Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England
CONCLUSIONS: Our results support the publication of national outcome data. If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment.PMID:35584974 | DOI:10.1016/j.clon.2022.04.012 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 18, 2022 Category: Cancer & Oncology Authors: N Wadd C Peedell C Polwart Source Type: research
Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England
CONCLUSIONS: Our results support the publication of national outcome data. If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment.PMID:35584974 | DOI:10.1016/j.clon.2022.04.012 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 18, 2022 Category: Cancer & Oncology Authors: N Wadd C Peedell C Polwart Source Type: research
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
CONCLUSIONS: In this study, we found a high SCR (67%) and mPR (35%) after ab-PC treatment for stage IIIA and IIIB potentially resectable LSCC. ab-PC maybe considered a neoadjuvant chemotherapy option for potentially resectable LSCC patients.PMID:35529791 | PMC:PMC9073738 | DOI:10.21037/tlcr-22-252 (Source: Cell Research)
Source: Cell Research - May 9, 2022 Category: Cytology Authors: Wenjuan Jiang Yuling Zhou Liang Zeng Yi Xiong Li Liu Chunhua Zhou Haiyan Yang Hui Guo Fabrizio Minervini Stefano Bongiolatti Nong Yang Yongchang Zhang Min Tao Source Type: research
Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports
We presented two patients treated with ICIs with heterogeneous responses. One patient had Merkel cell carcinoma in the right thigh, and the other had nasopharyngeal squamous carcinoma. The first patient was treated with sintilimab and the second with sintilimab combined with abraxane. In the first patient, subcutaneous lesions grew substantially after the first cycle of treatment with sintilimab. In the second patient, subcutaneous lesions grew gradually after the second cycle of treatment with sintilimab combined with abraxane. In both cases, biopsy examination confirmed that newly emerged lesions were metastases of the p...
Source: Cell Research - April 26, 2022 Category: Cytology Authors: Yong Da Ge Shen Ming Zhou Tao Wang Dapeng Dong Lina Bu Yun Shao Qiyun Sun Ruoying Yu Source Type: research
Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer
Nanomedicine, Ahead of Print. (Source: Nanomedicine)
Source: Nanomedicine - April 8, 2022 Category: Nanotechnology Authors: Weiwei Zhang Yinggang Xu Xiaoqing Shi Xiaofeng Huang Rui Chen Haiping Xu Wenjie Shi Xinyu Wan Ye Wang Jinzhi He Cuiying Li Jue Wang Xiaoming Zha Source Type: research
Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer
Nanomedicine, Ahead of Print. (Source: Future Medicine: Nanomedicine)
Source: Future Medicine: Nanomedicine - April 8, 2022 Category: Nanotechnology Authors: Weiwei Zhang Yinggang Xu Xiaoqing Shi Xiaofeng Huang Rui Chen Haiping Xu Wenjie Shi Xinyu Wan Ye Wang Jinzhi He Cuiying Li Jue Wang Xiaoming Zha Source Type: research
Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study
CONCLUSIONS: Induction nab-paclitaxel plus cisplatin, nimotuzumab combined with IMRT, followed by S-1 adjuvant chemotherapy, yielded an excellent survival benefit with tolerable toxicities in patients with stage N3 NPC. Distant metastasis was the main cause of treatment failure.PMID:35381746 | DOI:10.4103/jcrt.jcrt_2145_21 (Source: Cancer Control)
Source: Cancer Control - April 6, 2022 Category: Cancer & Oncology Authors: Liya Zhou Jie Lin Jiawei Chen Shuai Zhang Source Type: research
Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
ConclusionsNab-PTX + RAM exhibited more favorable trends in terms of PFS and OS but was more myelosuppressive than PTX + RAM. As neutropenia is commonly manageable toxicity, nab-PTX + RAM presents a treatment alternative for AGC. Further studies including randomized, controlled studies are warranted. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - March 28, 2022 Category: Cancer & Oncology Source Type: research
